Squarepoint
NPCE icon

Squarepoint’s Neuropace NPCE Stock Holding History

Squarepoint’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$394K Buy
29,936
+1,919
+7% +$28.8K ﹤0.01% 3501
2025
Q4 		$433K Sell
28,017
-33,580
-55% -$449K ﹤0.01% 3326
2025
Q3 		$635K Buy
61,597
+31,267
+103% +$295K ﹤0.01% 3045
2025
Q2 		$338K Buy
+30,330
New +$379K ﹤0.01% 3599
2024
Q2 		– Sell
-13,316
Closed -$176K – 4463
2024
Q1 		$176K Buy
+13,316
New +$190K ﹤0.01% 3652

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Squarepoint's NPCE Position: Q1 2026 in Review

Squarepoint increased its Neuropace (NPCE) stake by 6.8% in Q1 2026, buying an estimated $28.8K and bringing the position to 29,936 shares worth $394K. The position accounts for ﹤0.01% of the portfolio, ranked #3501.

Squarepoint first reported a position in NPCE in Q1 2024 and has held it in 5 quarters since. The position peaked at $635K in Q3 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Squarepoint held 29,936 shares of Neuropace worth $394K as of Q1 2026.
  • Squarepoint bought 1,919 Neuropace shares in Q1 2026, an estimated $28.8K.
  • Neuropace made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3501 holding.
  • Squarepoint first reported a position in Neuropace in Q1 2024 and has held it in 5 quarters since.
  • Squarepoint's Neuropace position peaked at $635K in Q3 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.